PlainRecalls
ModerateClass IIOngoing

FDA Drug recall · Reported August 12, 2026

Dicyclomine Hydrochloride Capsules, USP, 10mg, 1,000 bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India, NDC 59651-719-99

shortfill; reports of empty capsules.

Recall #
D-0733-2026
Affected scope
6,408 bottles distributed to market
Initiated
July 23, 2026
Verify with FDA Drug →
View my saved recalls

Aurobindo Pharma USA Inc recalled Dicyclomine Hydrochloride Capsules, USP, 10mg, 1,000 bottles, Rx only, Distributed by: Au… - a moderate-severity action.

Dicyclomine Hydrochloride Capsules, USP, 10mg, 1,000 bottles, Rx only, Distributed by: Au… was recalled by Aurobindo Pharma USA Inc in August 12, 2026. Reason: shortfill; reports of empty capsules.. Check the official notice for the remedy. Verify recall #D-0733-2026 with the FDA Drug before acting.

The recall

Aurobindo Pharma USA Inc issued this moderate-severity FDA Drug recall-shortfill; reports of empty capsules..

Moderate
severity level
Class II
classification
August 12, 2026
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0733-2026 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-0733-2026) was formally reported on August 12, 2026, with the manufacturer initiating the action on July 23, 2026. It is classified under Moderate severity (Class II), with a current status of Ongoing. Aurobindo Pharma USA Inc is listed as the recalling firm, operating out of East Windsor, NJ. Federal records list the affected scope as 6,408 bottles distributed to market.

The documented reason for this recall is: shortfill; reports of empty capsules. Distribution data in the federal record shows the product reached: US Nationwide.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category - 14,472 drugs & medications recalls on record

05001,0001,5002,000 2006201220152018202120242026 448
Severity1906864652High severity (most serious)Moderate severityLow severity
Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Dicyclomine Hydrochloride Capsules, USP, 10mg, 1,000 bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India, NDC 59651-719-99

Reason for recall

shortfill; reports of empty capsules.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Moderate (Class II)
Status Ongoing
Recall number D-0733-2026
Date reported August 12, 2026
Date initiated July 23, 2026
Recalling firm Aurobindo Pharma USA Inc
Firm location East Windsor, NJ
Affected scope 6,408 bottles distributed to market
Distribution US Nationwide.

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-0733-2026) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Dicyclomine Hydrochloride Capsules, USP, 10mg, 1,000 bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India, NDC 59651-719-99. Recalled by Aurobindo Pharma USA Inc. Units affected: 6,408 bottles distributed to market.
Why was this product recalled?
shortfill; reports of empty capsules.
Which agency issued this recall?
This recall was issued by the FDA Drug on August 12, 2026. Severity: Moderate. Recall number: D-0733-2026.
Where was the recalled product distributed?
Distribution: US Nationwide..
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported August 12, 2026. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026